PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR METASTATIC DISEASE IN THE UK
Abstract
Authors
D. Ntais R. Batteson R. Hart M. Hemstock D. Lee